Using nanoparticles to improve treatment for severe inflammation and sepsis
Multimodal Nanoparticles for Severe Inflammation and Sepsis
This study is exploring a new treatment using tiny particles to help boost the immune system in people with sepsis, a serious infection-related condition, with the hope of improving survival and reducing complications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11202126 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of immunotherapy using nanoparticles to enhance the immune response in patients suffering from sepsis, a severe and life-threatening condition caused by infections. The approach involves creating drug-free nanoparticles that can modulate the immune system to improve survival rates and reduce complications associated with sepsis. By testing these nanoparticles in animal models, the researchers aim to understand their effectiveness and safety before considering human trials. Patients may benefit from a more effective treatment option that addresses the complex nature of sepsis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with severe sepsis or septic shock who are experiencing an uncontrolled immune response to infection.
Not a fit: Patients with mild infections or those who do not meet the criteria for severe sepsis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves survival rates and reduces long-term complications for patients with sepsis.
How similar studies have performed: Previous research has shown promising results with nanoparticle-based therapies in other inflammatory conditions, suggesting potential for success in this novel application.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Pearson, Ryan Matthew — University of Maryland Baltimore
- Study coordinator: Pearson, Ryan Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.